Literature DB >> 33359600

Role of inflammatory chemokines in hypertension.

Tomasz P Mikolajczyk1, Piotr Szczepaniak2, Francesca Vidler3, Pasquale Maffia4, Gerard J Graham3, Tomasz J Guzik5.   

Abstract

Hypertension is associated with immune cells activation and their migration into the kidney, vasculature, heart and brain. These inflammatory mechanisms are critical for blood pressure regulation and mediate target organ damage, creating unique novel targets for pharmacological modulation. In response to angiotensin II and other pro-hypertensive stimuli, the expression of several inflammatory chemokines and their receptors is increased in the target organs, mediating homing of immune cells. In this review, we summarize the contribution of key inflammatory chemokines and their receptors to increased accumulation of immune cells in target organs and effects on vascular dysfunction, remodeling, oxidative stress and fibrosis, all of which contribute to blood pressure elevation. In particular, the role of CCL2, CCL5, CXCL8, CXCL9, CXCL10, CXCL11, CXCL16, CXCL1, CX3CL1, XCL1 and their receptors in the context of hypertension is discussed. Recent studies have tested the efficacy of pharmacological or genetic targeting of chemokines and their receptors on the development of hypertension. Promising results indicate that some of these pathways may serve as future therapeutic targets to improve blood pressure control and prevent target organ consequences including kidney failure, heart failure, atherosclerosis or cognitive impairment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-hypertensive drug; Chemokine; Chemokine receptor; Hypertension; Inflammation

Mesh:

Substances:

Year:  2020        PMID: 33359600     DOI: 10.1016/j.pharmthera.2020.107799

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  7 in total

1.  CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure.

Authors:  Yang Zhang; Yicong Ye; Xiaoqiang Tang; Hui Wang; Toshiko Tanaka; Ran Tian; Xufei Yang; Lun Wang; Ying Xiao; Xiaomin Hu; Ye Jin; Haiyu Pang; Tian Du; Honghong Liu; Lihong Sun; Shuo Xiao; Ruijia Dong; Luigi Ferrucci; Zhuang Tian; Shuyang Zhang
Journal:  J Exp Med       Date:  2022-06-10       Impact factor: 17.579

2.  Association of Pericardiac Adipose Tissue With Coronary Artery Disease.

Authors:  Mingxuan Li; Lin Qi; Yanglei Li; Shuyi Zhang; Lei Lin; Lijin Zhou; Wanlin Han; Xinkai Qu; Junfeng Cai; Maoqing Ye; Kailei Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

Review 3.  Programming of Vascular Dysfunction by Maternal Stress: Immune System Implications.

Authors:  Tiago J Costa; Júlio Cezar De Oliveira; Fernanda Regina Giachini; Victor Vitorino Lima; Rita C Tostes; Gisele Facholi Bomfim
Journal:  Front Physiol       Date:  2022-03-10       Impact factor: 4.566

4.  Induction of Collagen I by CXCL10 in Ovarian Theca-Stroma Cells via the JNK Pathway.

Authors:  Chaojun Wang; Yun Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-01       Impact factor: 6.055

5.  Identification of biomarkers, pathways and potential therapeutic agents for salt-sensitive hypertension using RNA-seq.

Authors:  Xiaoying Chao; Zhiyuan Jiang; Guoqiang Zhong; Rongjie Huang
Journal:  Front Cardiovasc Med       Date:  2022-08-10

Review 6.  Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications.

Authors:  Haixia Zhang; Ke Yang; Feng Chen; Qianqian Liu; Jingyu Ni; Weilong Cao; Yunqing Hua; Feng He; Zhihao Liu; Lan Li; Guanwei Fan
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

7.  Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy.

Authors:  Sai Ma; Jing Feng; Xiuyu Lin; Jing Liu; Yi Tang; Shinan Nie; Jianbin Gong; Lei Wang
Journal:  Oxid Med Cell Longev       Date:  2021-09-15       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.